Imac Holdings, INC 8-K filings

IMAC Holdings, Inc. has turned over its Ignite Proteomics subsidiary and related assets to a collateral agent, satisfying senior secured notes and addressing a default.

IMAC Holdings, Inc. issued a secured promissory note with a principal of $175,000, receiving only $125,000 from a lender.

IMAC Holdings, Inc. has issued a secured promissory note with a principal amount of $222,600 for a purchase price of $159,000, maturing on January 31, 2026.

IMAC Holdings, Inc. issued a secured promissory note for $292,600, receiving $209,000, due January 31, 2026.

IMAC Holdings, Inc. has entered into a Securities Purchase Agreement to issue $7.5 million in senior secured notes, backed by substantially all company assets, maturing January 31, 2026.

IMAC Holdings, Inc. has issued a secured promissory note for $260,400, receiving $186,000, maturing on January 31, 2026.

IMAC Holdings, Inc. issued a secured promissory note for $247,800, receiving $177,000, maturing on February 13, 2026.

IMAC Holdings, Inc. has issued a secured promissory note for a principal amount of $245,000, purchased for $175,000, maturing on February 13, 2026.

IMAC Holdings, Inc. has issued a $210,000 senior secured promissory note for a purchase price of $150,000, maturing in February 2026.

IMAC Holdings, Inc. has issued an unsecured promissory note for $285,600, receiving $204,000, due December 24, 2025.

IMAC Holdings, Inc. has issued an unsecured promissory note for $201,600, receiving $144,000, maturing on December 24, 2025.

IMAC Holdings, Inc. issued an unsecured promissory note for $296,800, receiving $212,000, which matures on December 24, 2025.

IMAC Holdings, Inc. issued an unsecured promissory note for $179,375 and announced the immediate resignation of director Michael D. Pruitt.

IMAC Holdings' Ignite Proteomics subsidiary partners with Inova Health to analyze up to 600 tumor samples for late-stage gastrointestinal cancer treatment guidance.

IMAC Holdings, Inc. issued an unsecured promissory note for $296,800, receiving $212,000, maturing on December 24, 2025.

IMAC Holdings, Inc. issued two unsecured promissory notes totaling $315,000 in principal for a combined purchase price of $225,000, maturing on December 24, 2025.

IMAC Holdings' subsidiary, Ignite Proteomics, announced a research collaboration with Vanderbilt University Medical Center to advance immuno-oncology biomarker discovery and issued an $84,000 promissory note.

IMAC Holdings, Inc. issued an unsecured promissory note for $30,800 at a discounted purchase price of $22,000, maturing December 24, 2025.

IMAC Holdings, Inc. has issued an unsecured promissory note with a principal amount of $175,000, receiving $125,000, maturing on December 24, 2025.

IMAC Holdings, Inc. announced the issuance of an unsecured promissory note for $350,000, received for a purchase price of $250,000, maturing in December 2025.

IMAC Holdings, Inc. has issued an unsecured promissory note with a principal amount of $84,000 for a purchase price of $60,000, maturing on December 24, 2025.

A recent filing reveals the company has issued a new promissory note for $198,800, maturing in December 2025, with an initial purchase price of $142,000.

IMAC Holdings, Inc. has issued an unsecured promissory note with a principal amount of $128,800, purchased for $92,000, maturing on December 24, 2025.

IMAC Holdings, Inc. announced it has issued an unsecured promissory note for $215,000, with a principal amount of $301,000, maturing on December 24, 2025.

IMAC Holdings, Inc. announced the appointment of Jason Lobel, a data-driven healthcare and tech entrepreneur, and Saundra Pelletier, a distinguished women's health pharmaceutical executive, to its Board of Directors, effective June 2, 2025.

IMAC Holdings, Inc. has announced the issuance of a $455,000 promissory note at a significant discount and the resignation of director Jeffrey Busch.

IMAC Holdings, Inc. announced it issued an unsecured promissory note for $82,600, receiving $59,000, which matures on December 24, 2025, indicating a high cost of capital.

IMAC Holdings announces it will restate previously issued financial statements from mid-2024 through the end of 2024 due to a non-cash error in accounting for preferred dividends.

IMAC Holdings, Inc. has entered into a financial agreement, issuing a senior note for $275,800 to bolster its financial position.

IMAC Holdings, Inc. has replaced its independent registered public accounting firm, Marcum LLP, with CBIZ CPAs, effective May 2, 2025.